@Coctaanatis LYMErix® was a vaccine developed by SmithKline Beecham (now GlaxoSmithKline) to prevent Lyme disease, a tick-borne illness caused by the bacterium Borrelia burgdorferi. The vaccine was approved by the U.S. Food and Drug Administration (FDA) in 1998 and was available for a few years before being voluntarily withdrawn from the market by the manufacturer in 2002. The decision to withdraw LYMErix® was primarily driven by low sales and concerns about potential lawsuits related to allegations of adverse effects associated with the vaccine. While the vaccine was generally considered safe and effective in preventing Lyme disease, some individuals reported experiencing symptoms similar to those of Lyme disease itself after receiving the vaccine. These reports led to public controversy and legal challenges that ultimately resulted in the withdrawal of LYMErix® from the market. Despite its withdrawal, research on Lyme disease and the development of new vaccines continues. There are ongoing efforts to create improved vaccines for Lyme disease prevention, but as of now, LYMErix® is no longer available for use.
CounterSocial is the first Social Network Platform to take a zero-tolerance stance to hostile nations, bot accounts and trolls who are weaponizing OUR social media platforms and freedoms to engage in influence operations against us. And we're here to counter it.
@Coctaanatis LYMErix® was a vaccine developed by SmithKline Beecham (now GlaxoSmithKline) to prevent Lyme disease, a tick-borne illness caused by the bacterium Borrelia burgdorferi. The vaccine was approved by the U.S. Food and Drug Administration (FDA) in 1998 and was available for a few years before being voluntarily withdrawn from the market by the manufacturer in 2002. The decision to withdraw LYMErix® was primarily driven by low sales and concerns about potential lawsuits related to allegations of adverse effects associated with the vaccine. While the vaccine was generally considered safe and effective in preventing Lyme disease, some individuals reported experiencing symptoms similar to those of Lyme disease itself after receiving the vaccine. These reports led to public controversy and legal challenges that ultimately resulted in the withdrawal of LYMErix® from the market. Despite its withdrawal, research on Lyme disease and the development of new vaccines continues. There are ongoing efforts to create improved vaccines for Lyme disease prevention, but as of now, LYMErix® is no longer available for use.